Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST. Jenkins DW, et al. Among authors: cho s. Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7. Mol Cancer Ther. 2012. PMID: 22679110
Delta-like ligand 4-notch blockade and tumor radiation response.
Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, Harris AL, Muschel RJ. Liu SK, et al. Among authors: cho s. J Natl Cancer Inst. 2011 Dec 7;103(23):1778-98. doi: 10.1093/jnci/djr419. Epub 2011 Oct 18. J Natl Cancer Inst. 2011. PMID: 22010178
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Cho S, Zammarchi F, Williams DG, Havenith CEG, Monks NR, Tyrer P, D'Hooge F, Fleming R, Vashisht K, Dimasi N, Bertelli F, Corbett S, Adams L, Reinert HW, Dissanayake S, Britten CE, King W, Dacosta K, Tammali R, Schifferli K, Strout P, Korade M 3rd, Masson Hinrichs MJ, Chivers S, Corey E, Liu H, Kim S, Bander NH, Howard PW, Hartley JA, Coats S, Tice DA, Herbst R, van Berkel PH. Cho S, et al. Mol Cancer Ther. 2018 Oct;17(10):2176-2186. doi: 10.1158/1535-7163.MCT-17-0982. Epub 2018 Jul 31. Mol Cancer Ther. 2018. PMID: 30065100
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, Harper J, Zhong H, Gao X, Yu XQ, Hinrichs MJ, Reed M, Kamal A, Strout P, Cho S, Woods R, Hollingsworth RE, Dixit R, Wu H, Gao C, Dimasi N. Thompson P, et al. Among authors: cho s. J Control Release. 2016 Aug 28;236:100-16. doi: 10.1016/j.jconrel.2016.06.025. Epub 2016 Jun 18. J Control Release. 2016. PMID: 27327768
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
de Bono JS, Fleming MT, Wang JS, Cathomas R, Miralles MS, Bothos J, Hinrichs MJ, Zhang Q, He P, Williams M, Rosenbaum AI, Liang M, Vashisht K, Cho S, Martinez P, Petrylak DP. de Bono JS, et al. Among authors: cho s. Clin Cancer Res. 2021 Jul 1;27(13):3602-3609. doi: 10.1158/1078-0432.CCR-20-4528. Epub 2021 Apr 1. Clin Cancer Res. 2021. PMID: 33795255 Clinical Trial.
Subcutaneous tunneling versus conventional insertion of peripherally inserted central catheters in hospitalized patients (TUNNEL-PICC): a multicentre, open-label, randomized, controlled trial.
Kim ET, Lee JH, Shim DJ, Kwon Y, Cho SB, Kim KJ, Kim D, Kim J, Kim ES, Jun H, Kim YJ, Kim J, Kim EJ, Kim CJ, Jun KI, Shin MJ, Yoon CJ, Lee S, Song SY, Won JH. Kim ET, et al. Among authors: cho sb. J Hosp Infect. 2024 Oct 25:S0195-6701(24)00356-6. doi: 10.1016/j.jhin.2024.10.008. Online ahead of print. J Hosp Infect. 2024. PMID: 39490586
20,185 results
You have reached the last available page of results. Please see the User Guide for more information.